Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 5/20 | 0.55 |
| ▸ | MMP3 | P08254 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343290 | 1.00 | CCR2 (0.57) | CCR2RAB9AMMP1MMP3MMP2 | |
| SCHEMBL25343287 | 1.00 | CCR2 (0.57) | CCR2RAB9AMMP1MMP3MMP2 | |
| SCHEMBL12875983 | 0.84 | CCR2 (0.64) | CCR2RAB9AMMP1MMP3MMP2 | |
| SCHEMBL12155589 | 0.84 | CCR2 (0.64) | CCR2RAB9AMMP1MMP3MMP2 | |
| SCHEMBL29481054 | 0.82 | CCR2 (0.55) | CCR2RAB9AMMP1MMP3MMP2 | |
| SCHEMBL3241217 | 0.80 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL319610 | 0.80 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL3487757 | 0.80 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL25344446 | 0.80 | CCR2 (0.60) | CCR2RAB9AMMP1MMP3MMP2 | |
| Hydrochloric Acid SCHEMBL25344436 | 0.80 | CCR2 (0.60) | CCR2RAB9AMMP1MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | CCR2 2998/4885RAB9A 924/4885MMP1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.